ESMO 2026: AstraZeneca Set To Expand Infimzi’s Bladder Cancer Reach With VOLGA

Sonesitatug vedotin, an antibody-drug conjugate developed by AstraZeneca, showed improved overall survival in patients with CLDN18.2-positive advanced gastroesophageal carcinoma in the CLARITY-Gastric01 trial. Median OS was 10.0 months vs 5.0 months for investigator’s choice in the third- or later-line population, meeting one primary end point. The drug also showed OS benefit in the intent-to-treat population.

Osimertinib plus savolitinib improved progression-free and overall survival in EGFR-mutated NSCLC patients with MET overexpression/amplification after osimertinib progression, per SAFFRON trial. Median PFS: 7.6 vs 5.4 months (HR 0.55, P < .001). Median OS: 17.8 vs 12.9 months (HR 0.68, P = .010). FDA application submitted in September 2026.

AstraZeneca's experimental stomach cancer drug, sonesitatug vedotin, showed promising results in a late-stage trial, doubling survival time. The company estimates potential annual sales of $5 billion. (AZN)

AstraZeneca reported Phase III trial results showing its drug sonesitatug vedotin reduced death risk by 42% in CLDN18.2-positive advanced gastric cancers, with median overall survival of 10.6 months vs 6.4 months. The data is potentially registrational and aligns with AstraZeneca's oncology strategy, pending regulatory filings and further readouts.

AstraZeneca's drug Sone-Ve doubled median survival to 10 months in patients with advanced gastric cancer in a trial. The drug reduced the risk of death by 53% in 3rd-line treatment. AstraZeneca plans to expand its use for CLDN18.2-positive cancers. The trial included 545 patients across 19 countries.

AstraZeneca's stomach cancer drug met its goal of extending overall survival in a late-stage study, according to the company. The drug's performance may impact investor sentiment and future valuation.